Literature DB >> 8033295

Comparison of 5-fluorouracil anabolite levels after intravenous bolus and continuous infusion.

T A Stein1, B Bailey, G P Burns.   

Abstract

The levels of 5-fluorouracil (5FU) and its anabolites in the serum, bile, pancreatic juice, liver, pancreas, and skeletal muscle of dogs were compared after single bolus administration and after continuous infusion. Six dogs had a bolus of 5FU (15 mg/kg) and were studied for 120 min. Five dogs had a continuous infusion of 5FU (30 mg/kg) and were studied for 24 h. After the bolus infusion, serum 5FU levels were initially high and then declined, whereas anabolite levels gradually increased over 45 min. Within 2 h, anabolite levels exceeded 5FU levels in tissues but were undetectable in bile and pancreatic juice. During the continuous infusion, anabolite levels in serum increased more rapidly than 5FU levels and remained significantly higher for 24 h. Anabolite levels also exceeded 5FU levels in bile, pancreatic juice, pancreas, and muscle but not in the liver. Continuous infusion of 5FU produced higher levels of the anabolites than did bolus infusion and maintained constant levels throughout the infusion period.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8033295     DOI: 10.1007/bf00686035

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  19 in total

Review 1.  5-Fluorouracil cardiotoxicity: a critical review.

Authors:  W J Gradishar; E E Vokes
Journal:  Ann Oncol       Date:  1990-11       Impact factor: 32.976

2.  Integration of chemotherapy into combined modality treatment of solid tumors VII. Adenocarcinoma of the breast.

Authors:  S K Carter
Journal:  Cancer Treat Rev       Date:  1976-09       Impact factor: 12.111

Review 3.  The pharmacology of the fluoropyrimidines.

Authors:  C E Myers
Journal:  Pharmacol Rev       Date:  1981-03       Impact factor: 25.468

Review 4.  5-Fluorouracil by protracted venous infusion. A review of current progress.

Authors:  R M Hansen; E Quebbeman; T Anderson
Journal:  Oncology       Date:  1989       Impact factor: 2.935

5.  Blood-pancreatic juice barrier to antibiotic excretion.

Authors:  G P Burns; T A Stein; L S Kabnick
Journal:  Am J Surg       Date:  1986-02       Impact factor: 2.565

6.  Continuous 5-fluorouracil infusion in refractory carcinoma of the breast.

Authors:  R Hansen; E Quebbeman; P Beatty; P Ritch; T Anderson; D Jenkins; J Frick; R Ausman
Journal:  Breast Cancer Res Treat       Date:  1987-11       Impact factor: 4.872

7.  5-Fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators.

Authors:  B Patel; R A Kloner; J Ensley; M Al-Sarraf; J Kish; J Wynne
Journal:  Am J Med Sci       Date:  1987-10       Impact factor: 2.378

8.  The relationship between plasma pharmacokinetics and tissue metabolites of 5-fluorouracil (5-FU) in patients with colorectal cancer.

Authors:  P J Finan; E M Chisholm; L Woodhouse; G R Giles
Journal:  Eur J Surg Oncol       Date:  1987-08       Impact factor: 4.424

9.  Continuous systemic 5-fluorouracil infusion in advanced colorectal cancer: results in 91 patients.

Authors:  R Hansen; E Quebbeman; R Ausman; J Frick; P Ritch; W Schulte; C Haas; P Beatty; T Anderson
Journal:  J Surg Oncol       Date:  1989-03       Impact factor: 3.454

10.  Alpha-2 interferon and 5-fluorouracil in advanced colorectal cancer.

Authors:  A Fornasiero; O Daniele; C Ghiotto; S M Aversa; P Morandi; M V Fiorentino
Journal:  Tumori       Date:  1990-08-31
View more
  2 in total

1.  The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity.

Authors:  S Hamzic; N Wenger; T K Froehlich; M Joerger; S Aebi; C R Largiadèr; U Amstutz
Journal:  Pharmacogenomics J       Date:  2016-03-22       Impact factor: 3.550

2.  Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer: relationships with toxicities.

Authors:  M Barberi-Heyob; B Weber; J L Merlin; C Dittrich; E A de Bruijn; E Luporsi; F Guillemin
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.